Common β1-AR coding SNPs and in vitro/in vivo drug responses
| Amino Acid Change | Nucleotide Change | Drug Response Studied | Genetic Association Noted | Reference |
|---|---|---|---|---|
| Ser49Gly | 145 A→G | Increased basal and agonist-stimulated AC | Yes | Levin et al., 2002 |
| Ser49Gly | 145 A→G | Increased agonist-promoted down-regulation | Yes | Levin et al., 2002; Rathz et al., 2002 |
| Ser49Gly or Gly389Arg | 145 A→G 1165 G→C | Potency/efficacy of NE cardiostimulant effects in right atrium of patients with CAD with/without β1AR blockade | No | Molenaar et al., 2002 |
| Gly389Arg | 1165G→C | Arg389 increased basal and agonist-stimulated AC, increased agonist-promoted binding | Yes | Mason et al., 1999 |
| Gly389Arg | 1165G→C | Catecholamine-induced lipolysis (adipocytes) | No | Ryden et al., 2001 |
| Gly389Arg | 1165G→C | Inotropic potency of NE (myocardial tissue) | Yes | Sandilands et al., 2003 |
| Gly389Arg | 1165G→C | Hemodynamic response to NE | No | Snapir et al., 2003a |
| Gly389Arg | 1165G→C | BP or heart rate with/without β1AR blockade | No | O'Shaughnessy et al., 2000 |
| Gly389Arg | 1165G→C | Arg389 larger decrease in resting systolic and mean arterial BP when treated with β-blocker (atenolol) | Yes | Sofowora et al., 2003 |
| Ser49Gly, Gly389Arg, and haplotype pair | 145 A→G 1165 G→C | Metoprolol treatment: Arg389 homozygotes greater reduction in DBP, haplotype pair (Ser49Arg389/Ser49Arg389) significant predictor of decrease in DBP | Yes | Johnson et al., 2003 |
CAD, coronary artery disease; DBP, diastolic blood pressure.